• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Respir Rev . COVID-19 pneumonia: pathophysiology and management

tetano

Editor, Senior Moderator
Eur Respir Rev


. 2021 Oct 20;30(162):210138.
doi: 10.1183/16000617.0138-2021. Print 2021 Dec 31.
COVID-19 pneumonia: pathophysiology and management


Luciano Gattinoni[SUP] 1 [/SUP], Simone Gattarello[SUP] 2 [/SUP], Irene Steinberg[SUP] 2 [/SUP], Mattia Busana[SUP] 2 [/SUP], Paola Palermo[SUP] 2 [/SUP], Stefano Lazzari[SUP] 2 [/SUP], Federica Romitti[SUP] 2 [/SUP], Michael Quintel[SUP] 2 3 [/SUP], Konrad Meissner[SUP] 2 [/SUP], John J Marini[SUP] 4 [/SUP], Davide Chiumello[SUP] 5 [/SUP], Luigi Camporota[SUP] 6 [/SUP]



Affiliations

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia is an evolving disease. We will focus on the development of its pathophysiologic characteristics over time, and how these time-related changes determine modifications in treatment. In the emergency department: the peculiar characteristic is the coexistence, in a significant fraction of patients, of severe hypoxaemia, near-normal lung computed tomography imaging, lung gas volume and respiratory mechanics. Despite high respiratory drive, dyspnoea and respiratory rate are often normal. The underlying mechanism is primarily altered lung perfusion. The anatomical prerequisites for PEEP (positive end-expiratory pressure) to work (lung oedema, atelectasis, and therefore recruitability) are lacking. In the high-dependency unit: the disease starts to worsen either because of its natural evolution or additional patient self-inflicted lung injury (P-SILI). Oedema and atelectasis may develop, increasing recruitability. Noninvasive supports are indicated if they result in a reversal of hypoxaemia and a decreased inspiratory effort. Otherwise, mechanical ventilation should be considered to avert P-SILI. In the intensive care unit: the primary characteristic of the advance of unresolved COVID-19 disease is a progressive shift from oedema or atelectasis to less reversible structural lung alterations to lung fibrosis. These later characteristics are associated with notable impairment of respiratory mechanics, increased arterial carbon dioxide tension (P [SUB]aCO[SUB]2[/SUB][/SUB] ), decreased recruitability and lack of response to PEEP and prone positioning.
 
Back
Top Bottom